Tier 3 — preclinical
Identification of and Molecular Basis for SIRT6 Loss-of-Function Point Mutations in Cancer
Cell Reports
2015
13(3):479-488
Bibliography
- PubMed
- PMID 26456828
- Funding
- Supported by NIH grants including R01 CA175727, R21 CA198109, R01 GM093072, R01 GM065386, DK088190 and Canadian Institutes of Health Research support.
Study snapshot
| Design | Cancer-genomics identification of patient-derived mutations plus biochemical and cell-function experiments. |
|---|---|
| Model | Human cancer-associated SIRT6 variants and SIRT6-knockout/rescue cellular models. |
| Sample | Multiple patient-derived variants and mechanistic cellular assays. |
| Intervention | Expression and functional testing of cancer-associated SIRT6 point mutations. |
| Duration | Experimental. |
| Endpoints | SIRT6 protein stability; Histone deacetylase activity; Glycolytic gene acetylation; Tumorigenic potential |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified



